Sun Pharma starts trial on plant based dengue drug candidate for Covid-19
This is the first phytopharmaceutical drug (plant based) that the country's drug regulator has approved for clinical trials for Covid-19.05-06-2020
05-06-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to initiation of phase II clinical trial on AQCH, which we shall be releasing after sending this letter to you.05-06-2020
Sun Pharma to test two drugs for treatment of Covid-19, stock up 3.5%
At present there are three clinical trials underway to test nafamostat in Covid19 patients around the world29-05-2020
Buy Sun Pharmaceutical Industries; target of Rs 540: ICICI Direct
ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 540 in its research report dated May 28, 2020.29-05-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to approval from DCGI to initiate clinical trial with Nafamostat in Covid-19 patients, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,29-05-2020
Specialty products segment key to Sun Pharma's growth prospects
Pricing pressure in US, lockdown may dent near-term prospects29-05-2020
Hold Sun Pharmaceutical Industries; target of Rs 467: Prabhudas Lilladher
Prabhudas Lilladher recommended Hold rating on Sun Pharmaceutical Industries with a target price of Rs 467 in its research report dated May 28, 2020.28-05-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to license agreement for SCD-044 between Sun Pharma and SPARC.28-05-2020
Earnings Call Transcript - Q4FY20 for Sun Pharmaceutical Industries
Conference Call with Sun Pharmaceuticals Management and Analysts on Q4FY20 and Full Year Earnings Performance and Outlook. Listen to the full earnings transcript. Key Remarks from Dilip Shanghvi, Managing Director, on consolidated financials and performance Our main focus has been to maintain continuity of product availability, and ensure patients continue getting their medications during this pandemic. We have focused on the supply chain and business, and done a good job. There were initially multiple disruptions in manufacturing due to lack of raw materials, we ensured availability of products nevertheless. Consolidated sales for Q4 was Rs. 8,078 crore, a growth of approx 15% YoY, and for the entire year we saw sales of Rs. 32,325 crore, a growth of 13% over FY19. EBITDA for the full year was Rs. 6,477 crore, a growth of 9% over the previous year. Key growth drivers include India, our global specialty businesses, and ROW and API businesses. While we focus on controlling costs and improving efficiencies, COVID19 is likely to change how we conduct business for a short while. A key focus for us will be employee protection, digital engagement with doctors and patients, supply chain protection, optimal utilization of our factories, supply continuity, and improving productivity plus throughout. We are also focusing on cash collection, cash preservation, and reduction in overall debt. We estimate some softening of sales in the near term due to lockdown and some stockpiling by customers. It's difficult to quantify the exact impact here. Specialty business We are witnessing consistent progress in global specialty revenue. Q4 saw $126 million specialty business revenues across markets. Specialty R&D; was 24% of total R&D; spend for the quarter. Ilumia alone accounted for $94 million in sales globally in its first full year of commercialization. In Q4 we saw material expenses increase YoY due to product mix and material cost involving Taro. The EBITDA margin at 15.5% in Q4, was lower mainly due to forex losses compared to Q3. The forex loss accounted for almost all of the fall in EBITDA margin, besides the increase in material and staff cost. Adjusted net profit was Rs. 660 crore excluding impact of exceptional items of Rs. 260 crores.27-05-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to fourth quarter FY20 financials,27-05-2020